Research programme: corticotropin releasing factor receptor antagonists - Taisho Pharmaceutical/Janssen Pharmaceutica

Drug Profile

Research programme: corticotropin releasing factor receptor antagonists - Taisho Pharmaceutical/Janssen Pharmaceutica

Alternative Names: CRA 0316; CRA 0450; CRA 1000; CRA 1001; CRA 1065; R 278995

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Pharmaceutica; Taisho Pharmaceutical
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists; Corticotropin releasing factor receptor 2 antagonists; Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 08 Aug 2017 Discontinued - Preclinical for Anxiety disorders in Japan (unspecified route)
  • 08 Aug 2017 Discontinued - Preclinical for Major depressive disorder in Japan (unspecified route)
  • 21 Oct 2009 Preclinical development in Anxiety disorders is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top